EXPLORER-HCM: percentage of patients who experienced a reduction in post-exercise LVOT peak gradient to <50 mmHg and <30 mmHg at Week 301
These data were exploratory in nature and results should be interpreted with caution. While these exploratory endpoints were prespecified, they were not powered for significance. Significant results may arise by chance and may not be generalisable1
Exploratory endpoint
Percentage of patients who experienced a reduction in post-exercise LVOT peak gradient to <50 mmHg at Week 301
Treatment difference, 53.5%; 95% CI: 42 to 65
Adapted from Olivotto I et al. 2020.1
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
The guideline-based threshold for invasive septal reduction therapy is an LVOT gradient ≥50 mmHg3,4
Exploratory endpoint
Percentage of patients who experienced a reduction in post-exercise LVOT peak gradient to <30 mmHg at Week 301
Treatment difference, 49.6%; 95% CI: 39.3 to 59.9
Adapted from Olivotto I et al. 2020.1
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
The guideline-based diagnostic criteria for obstruction is an LVOT gradient ≥30 mmHg3,4
Please refer to the CAMZYOS Summary of Product Characteristics for further information on dosing, initiation and safety.
CI, confidence interval; LVOT, left ventricular outflow tract; SoC, standard of care.
